Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes-Reference-Cited by-同舟云学术

Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes

Published:2017-09 Issue: Volume:28 Page:v372-v373
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Haddad R.,Blumenschein G.,Fayette J.,Guigay J.,Colevas A.D.,Licitra L.,Kasper S.,Vokes E.E.,Worden F.,Saba N.F.,Tahara M.,Concha-Benavente F.,Monga M.,Lynch M.,Li L.,Shaw J.W.,Gillison M.L.,Harrington K.J.,Ferris R.L.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/suppl_5/mdx374.001/19940158/mdx374.001.pdf

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck;Oral Oncology;2023-10

2. SN‐38, an active metabolite of irinotecan, enhances anti‐PD‐1 treatment efficacy in head and neck squamous cell carcinoma;The Journal of Pathology;2023-02-24

3. Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects;Technology in Cancer Research & Treatment;2023-01

4. Patterns of Response to Immune Oncology Drugs: How Relevant Are They in SCCHN?;Critical Issues in Head and Neck Oncology;2023

5. Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma;International Journal of Molecular Sciences;2021-05-07